David I. Quinn, MD

Clinical Professor of Medicine

Image of David I. Quinn, MD
Is this your profile? Click to edit

Overview

David Ian Quinn MBBS Honors Class I, PhD, FRACP FACP is an international expert in the field of clinical trials and molecular correlative studies in genitourinary cancer. Dr. Quinn is the medical director of the Norris Cancer Hospital and Clinics, head of the Section of Genitourinary Medical Oncology and associate professor of Medicine in the Division of Cancer Medicine and Blood Diseases at the Keck School of Medicine of USC. Prior experience includes Directorship of the Clinical Investigation Support Office and Leadership of the Genitourinary Cancer and Developmental Therapeutics Programs for the USC Norris Comprehensive Cancer Center.

He is a medical oncologist with focus in the field of clinical trials and molecular correlative studies in genitourinary cancer and early therapeutics. David Quinn has published more than 200 papers, reviews and chapters including recent publications in the journals Cancer Research, Clinical Cancer Research, Oncogene, Proceedings of the National Academy of Science, Journal of the National Cancer Institute, Lancet, Lancet Oncology, New England Journal of Medicine and Journal of Clinical Oncology. Dr. Quinn is a reviewer for more than 50 peer-reviewed journals and is on the editorial boards of is on the editorial boards of American Journal of Clinical Oncology, cancer.net (American Society of Clinical Oncology), Clinical Genitourinary Cancer, Bladder Cancer and Annals of Oncology. Dr. Quinn is a member of the NCI Prostate Cancer Task Force, Co-Chair for Genitourinary Cancer in the California Cancer Consortium and is SWOG organ site chair for advanced prostate cancer. He is a full member of the Department of Defense Integration Panel for Prostate Cancer Awards and has been an invited speaker in more than 40 countries.

Dr. Quinn’s current focus is on clinical trials and translation applications at USC and with SWOG and the California Cancer Consortium, where he has been principal investigator on more than 100 clinical trials for locally advanced and castrate-resistant prostate cancer, high grade urothelial cancer, advanced renal cell cancer, refractory germ cell tumors and adrenocortical carcinoma.

Awards

  • University of New South Wales: Gordon Lowe Memorial Prize, 1987
  • University of New South Wales: Honours First Class Bachelor of Medicine, Bachelor of Surgery, 1987
  • National Health and Medical Research Council of Australia: Postgraduate Medical Scholarship, 1996
     – 1999
  • Postgraduate Medical Council of New South Wales: Distinguished Contribution Award, 2000
  • St. Vincent’s Clinic Foundation: The David Wilson Travelling Fellowship, 2000
  • National Health and Medical Research Council of Australia: Neil Hamilton Fairley Fellowship, 2000
     – 2003
  • Royal Australasian College of Physicians: Vincent Fairfax Family Fellowship, 2001
  • USC Norris Cancer Center and Hospital: The Spirit of Norris Award, 2002
  • Castle Connolly Medical: America’s Top Doctors, 2010

Research Funding

  • NCTN – Network Lead Academic Participating Site: USC
    NIH · UG1CA180830 · Apr 17, 2014 – Feb 29, 2032 · Role: Co-Principal Investigator
  • NCI NCTN- Network Lead Academic Participating Site: USC
    NIH · U10CA180830 · Apr 17, 2014 – Feb 28, 2019 · Role: Co-Principal Investigator

Publications

  • The United Kingdom’s experience of controlled donation after circulatory death direct procurement of lungs with concomitant abdominal normothermic regional perfusion with an analysis of short-term outcomes. J Heart Lung Transplant. 2025 Aug; 44(8):1307-1318.. View in PubMed
  • A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma. Cancer Med. 2025 Apr; 14(7):e70725.. View in PubMed
  • Cost-effectiveness of Left Ventricular Assist Devices (LVADs) as destination therapy in the UK: An economic modelling study. PLoS One. 2024; 19(12):e0312912.. View in PubMed
  • Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Netw Open. 2024 10 01; 7(10):e2437871.. View in PubMed
  • Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial. Eur Urol. 2025 Nov; 88(5):462-471.. View in PubMed
  • Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for advanced heart failure: systematic review and economic evaluation. Health Technol Assess. 2024 08; 28(38):1-237.. View in PubMed
  • Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma. Oncotarget. 2024 07 10; 15:444-458.. View in PubMed
  • Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors. J Clin Oncol. 2024 09 01; 42(25):3033-3046.. View in PubMed
  • Development of a quality of life measure for left ventricular assist device recipients using a mixed methods approach. ESC Heart Fail. 2024 Oct; 11(5):3167-3179.. View in PubMed
  • Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. Eur Urol Oncol. 2024 Oct; 7(5):1097-1104.. View in PubMed